Abstract
Tamoxifen causes an objective response in about one-third of metastatic breast cancer and in only half of the breast cancer patients with estrogen receptor (ER) positive tumors. Steroid-receptor coactivator-1 (SRC-1) appears to be a general coactivator for steroid receptors and rate limiting factor necessary for efficient ER transactivation. We aimed to evaluate whether SRC-1 expression is an additional factor for prediction of response to first-line tamoxifen therapy in patients who developed recurrent disease. Here for the first time, we report on SRC-1 expression using a semi-quantitative RT-PCR in 21 primary breast tumors, seven mammary tumor cell-lines, 12 fibroblast cultures, and six normal breast tissues. The highest levels of SRC-1 were observed in normal tissues, intermediate levels in tumor tissues, and the lowest levels in breast tumor cell-lines. There was no relationship between the levels of SRC-1 in these primary tumors and the proportion of tumor cells within the surgical samples, nor with ER status. The median SRC-1 level was, however, lower in tumors from patients that did not respond to tamoxifen. Our findings suggest that high levels of SRC-1 indicate a favorable response to tamoxifen of patients with recurrent breast cancer. Abbreviations: PgR, progesterone receptor; ER, estrogen receptor; GR, glucocorticoid receptor; TR, thyroid hormone receptor; RXR, retinoid X receptor; SRC-1, steroid-receptor coactivator-1; EGF, epidermal growth factor; TGF, transforming growth factor; IGF, insulin like growth factor; UPA, urokinase-type plasminogen activator
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Katzenellenbogen BS, Montano MM, Ekena K, Herman ME, McInerney EM: Antiestrogens: Mechanisms of action and resistance in breast cancer. Breast Cancer Res Treat 44: 23–38, 1997
Klijn JGM, Berns EMJJ, Bontenbal M, Foekens JA: Cell biological factors associated with the response of breast cancer to systemic treatment. Cancer Treat Rev 19: 45–63, 1993
Klijn JGM, Berns EMJJ, Foekens JA: Prognostic factors and response to therapy in breast cancer. Cancer Surv 18: 165–198, 1993
Foekens JA, Look MP, Peters HA, van Putten WlJ, Portengen H, Klijn JGM: Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 predict poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 87: 751–756, 1995
Beato M, Sanchez-Pacheco A: Interaction of steroid hormone receptors with the transcription initiation complex. Endocrine Rev 17: 587–609, 1996
Oñate SA, Tsai SY, Tsai MJ, O'Malley BW: Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270: 1354–1357, 1995
Ravdin PM, Green S, Dorr TM: Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study. J Clin Oncol 10: 1284–1291, 1992
Foekens JA, Portengen H, Look MP, van Putten WLJ, Thirion B, Bontenbal M, Klijn JGM: Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer. Br J Cancer 70: 1217–1223, 1994
Foekens JA, Portengen H, van Putten WLJ, Peters HAM, Krijnen E, Alexieva-Figusch J, Klijn JGM: Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast cancer. Cancer Res 49: 5823–5828, 1989
van Roozendaal KEP, Klijn JGM, van Ooijen B, Claassen C, Eggermont AMM, Henzen-Logmans SC, Foekens JA: Differential regulation of breast tumor cell proliferation by stromal fibroblasts of various breast tissue sources. Int J Cancer 65: 120–125, 1996
Gibbs RA, Nguyen PN, McBride LJ, Koepf SM, Caskey T: Identification of mutations leading to the Lesch-Nyhan syndrome by automated direct DNA sequencing of in vitro amplified cDNA. Proc Natl Acad Sci USA 86: 1919–1923, 1989
Heery DM, Kalkhoven E, Hoare S, Parker MG: A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387: 733–736, 1997
Smith CL, Nawaz Z, O'Malley BW: Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endo 11: 657–666, 1997
McInerney EM, Tsai MJ, O'Malley BW, Katzenellenbogen BS: Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator. Proc Natl Acad Sci USA 93: 10069–10073, 1996
Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Gloss B, Lin SC, Heyman RA, Rose DW, Glass CK, Rosenfeld MG: A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85: 403–414, 1996
Smith CL, Oñate SA, Tsai MJ, O'Malley BW: CREB binding protein acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription. Proc Natl Acad Sci USA 93: 8884–8888, 1996
Yao TP, Ku G, Zhou N, Scully R, Livingston DM: The nuclear hormone receptor coactivator SRC-1 is a specific target of p300. Proc Natl Acad Sci USA 93: 10626–10631, 1996
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Berns, E.M., van Staveren, I.L., Klijn, J.G. et al. Predictive value of SRC-1 for tamoxifen response of recurrent breast cancer. Breast Cancer Res Treat 48, 87–92 (1998). https://doi.org/10.1023/A:1005903226483
Issue Date:
DOI: https://doi.org/10.1023/A:1005903226483